Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

The conversation jokes about hair loss treatments, mentioning finasteride, minoxidil, dutasteride, microneedling, ketoconazole shampoo, and rosemary oil as if they were players in a game. Some users also discuss the use of finasteride for prostate issues and the possibility of splitting the dose.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

A dermatologist recommended PRP (Platelet Rich Plasma) and GFC (Growth Factor Concentrate) for pattern baldness, but online sources suggest they may not be effective. The user is seeking opinions on these treatments.

The conversation discusses using RU58841 with octopirox or essential oils for hair loss treatment. The user is seeking advice on which variation to try.

The user is considering a hair transplant and is using topical finasteride, minoxidil, antiandrogens, ketoconazole shampoo, and serenoa repens. They are deciding between surgeons Dogan Turan and Bruno Pinto, and are concerned about the technique and potential complications due to diffuse hair loss.

Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

A female user is experiencing severe hair loss, especially at the crown and front, with broken and dull hair despite using Moroccan oil, shea moisture shampoo, and coconut oil. She seeks recommendations for a clinic or doctor as previous doctors attributed the issue to stress but offered no solutions.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The user is exploring hair loss treatments, including Patented Growth Factors (PGF) and a serum with Copper Peptide, Ceramides, Amino Acids, and Caffeine, while expressing concerns about the cost and effectiveness of PGF. They are also considering starting finasteride due to doubts about PGF's long-term viability and are seeking experiences from others who have used these treatments alongside antidepressants.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

A 40+ year-old male used finasteride and minoxidil sprays daily, later adding a PEMF hat to his routine, resulting in noticeable hair regrowth in the crown area after 6 months. He plans to continue the treatment and update at 12 months.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.